The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
01-Jun-22
$537 million
Target:
NAC 33 & NAC 34, subsidiaries of Nordic Aviation Capital
Acquiror:
Azorra Aviation
Advised Azorra Aviation, a leading commercial aircraft lessor backed by Oaktree Capital Management, on the chapter 11 restructuring and related investment in NAC 33 & 34, two exiting subsidiaries of Nordic Aviation Capital
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
24-Nov-20
$1.5 billion
Target:
Cirque du Soleil
Acquiror:
Ad Hoc Group of Lenders
Advised the Company on its CCAA and Ch.15 proceedings and $1.5bn sale through a Sale and Investment Solicitation Process (SISP)
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
24-Feb-15
$NA
Target:
Azelis Group (majority owned by 3i)
Acquiror:
Funds advised by Apax Partners
Advised 3i on the sale of Azelis Group, a leading pan-European distributor of specialty chemicals with an emerging presence in Asia, to funds advised by Apax partners
03-Mar-14
$3.6 billion
Target:
hibu plc (formerly Yell Group plc)
Advised hibu, a full service provider of digital and print marketing services for SMEs and owner of print directory brands Yellow Pages (UK), Yellowbook (US) and Paginas Amarillas (Spain), on the comprehensive restructuring of its £2.2 billion balance sheet debt
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
21-Jul-09
$2.8 billion
Target:
Quebecor World Inc
Acted as financial advisor to Quebecor World on its CCAA / Chapter 11 restructuring
15-Oct-02
$3.2 billion
Target:
AT&T Canada
Advised AT&T Canada on a stand-alone financial restructuring